Kronos Bio Announces Selection Of Autoimmune Development Candidate For Sjögren's Disease; Preclinical Data For KB-7898 Will Be Presented At ACR Convergence 2024; Plans To Initiate IND-Enabling Studies Of KB-7898 In Q4 2024
Portfolio Pulse from Benzinga Newsdesk
Kronos Bio has announced the selection of KB-7898, a p300 KAT inhibitor, as a development candidate for Sjögren's disease. Preclinical data will be presented at ACR Convergence 2024, with IND-enabling studies planned for Q4 2024. KB-7898 is Kronos Bio's first autoimmune disease candidate.
October 07, 2024 | 12:57 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Kronos Bio has nominated KB-7898 as a development candidate for Sjögren's disease, marking its first foray into autoimmune diseases. Preclinical data will be shared at ACR Convergence 2024, with IND-enabling studies set for Q4 2024.
The announcement of KB-7898 as a development candidate for Sjögren's disease is significant for Kronos Bio as it represents their entry into the autoimmune disease market. The presentation of preclinical data and the initiation of IND-enabling studies are positive steps that could boost investor confidence and potentially lead to future revenue streams if successful.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100